Abstract: The present specification provides a drug that causes highly-efficient skipping of exon 51 in the human dystrophin gene. The present specification provides an antisense oligomer having an activity to induce skipping of exon 51 in the human dystrophin gene.
Type:
Grant
Filed:
August 25, 2022
Date of Patent:
October 10, 2023
Assignees:
NIPPON SHINYAKU CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY
Abstract: Provided herein are RNAi molecules including a first strand containing a guide sequence and a second strand comprising a non-guide sequence where the non-guide sequence contains a bulge opposite the seed region of the guide sequences; e.g., opposite the cleavage sequence. In some aspects, the invention provides RNAi for treating Huntington's disease. Further provided herein are expression cassettes, vectors (e.g., rAAV, recombinant adenoviral, recombinant lentiviral, and recombinant HSV vectors), cells, viral particles, and pharmaceutical compositions containing the RNAi. Yet further provided herein are methods and kits related to the use of the RNAi, for example, to treat Huntington's disease.
Type:
Grant
Filed:
July 28, 2020
Date of Patent:
October 10, 2023
Assignee:
Genzyme Corporation
Inventors:
Lisa M. Stanek, Adam Palermo, Brenda Richards, Sergio Pablo Sardi, Catherine O′Riordan, Antonius Song
Abstract: The present invention refers to an inhibitor consisting of oligonucleotides comprising 10 to 25 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of C/EBP-homologous protein (Chop) of SEQ ID NO.1 (human) and/or SEQ ID NO. 48 (human) but also with mouse and rat sequences, wherein the oligonucleotide N inhibits at least 50% of the Chop expression. The invention is further directed to a pharmaceutical composition comprising such oligonucleotide.
Type:
Grant
Filed:
September 28, 2018
Date of Patent:
October 10, 2023
Assignee:
Secarna Pharmaceuticals GmbH & Co. KG
Inventors:
Richard Klar, Frank Jaschinski, Sven Michel
Abstract: Provided herein are methods of treating a coronavirus infection in a patient, comprising administering an agent to the patient in an amount effective to increase cellular lysosomal pH in cells of the patient. As provided herein, the agent is one or more of an agent for reducing expression or activity of nuclear receptor coactivator 7 (NCOA7) in the patient, an RNAi agent or antisense reagent for knocking down expression of a v-rel avian reticuloendotheliosis viral oncogene homolog A (RelA/p65) transcript, or a janus kinase (JAK) inhibitor, thereby increasing cellular lysosomal pH in cells of the patient.
Type:
Grant
Filed:
March 31, 2021
Date of Patent:
October 3, 2023
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Inventors:
Stephen Yu-Wah Chan, LLoyd David Harvey
Abstract: This disclosure provides compositions and methods of using these compositions to mediate a targeted trans-splicing event on a pre-mRNA in a cell.
Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's Disease (HD) progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntington's Disease (HD) in an individual susceptible to Huntington's Disease (HD). Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
Abstract: The invention relates to inhibitory nucleic acids and rAAV-based compositions, methods and kits useful for treating Amyotrophic Lateral Sclerosis.
Type:
Grant
Filed:
February 12, 2021
Date of Patent:
September 19, 2023
Assignee:
University of Massachusetts
Inventors:
Christian Mueller, Robert H. Brown, Jr.
Abstract: Long-chain non-coding RNA NEAT1 are used in the preparation of drugs for the treatment of Fuchs' endothelial corneal dystrophy. Overexpression of the long-chain non-coding RNA NEAT1 can effectively reduce corneal endothelial damage, alleviate the symptoms of corneal edema, can be used for the treatment of Fuchs' endothelial corneal malnutrition.
Type:
Grant
Filed:
October 7, 2022
Date of Patent:
September 19, 2023
Assignee:
Eye Institute of Shandong First Medical University
Abstract: Embodiments herein provide specially designed synthetic BCL11A-targeting microRNAs for RNA polymerase II expression, and methods of use to treat hemoglobinopathies such as sickle cell disease or thalassemia by increasing the expression levels of fetal hemoglobin levels.
Type:
Grant
Filed:
August 17, 2021
Date of Patent:
August 29, 2023
Assignee:
THE CHILDREN'S MEDICAL CENTER CORPORATION
Inventors:
Michael Milsom, David A. Williams, Richard Gregory
Abstract: Certain embodiments disclosed herein are directed to compounds and methods for modulating APP expression. In certain embodiments, modulating the splicing of amyloid precursor protein (APP) reduces amyloid ? (A?) production.
Type:
Grant
Filed:
March 1, 2019
Date of Patent:
August 22, 2023
Assignees:
Ionis Pharmaceuticals, Inc., Rosalind Franklin University of Medicine and Science
Abstract: In various aspects and embodiments the invention provides compositions and methods useful in the treatment of inflammatory disease, in particular, multiple sclerosis.
Type:
Grant
Filed:
May 7, 2019
Date of Patent:
August 8, 2023
Assignee:
YALE UNIVERSITY
Inventors:
Jeffrey Bender, Vinod Ramgolam, Timur Yarovinsky
Abstract: The present invention provides novel, stable lipid particles having a non-lamellar structure and comprising one or more active agents or therapeutic agents, methods of making such lipid particles, and methods of delivering and/or administering such lipid particles. More particularly, the present invention provides stable nucleic acid-lipid particles (SNALP) that have a non-lamellar structure and that comprise a nucleic acid (such as one or more interfering RNA), methods of making the SNALP, and methods of delivering and/or administering the SNALP.
Type:
Grant
Filed:
March 16, 2021
Date of Patent:
August 8, 2023
Assignee:
ARBUTUS BIOPHARMA CORPORATION
Inventors:
Ed Yaworski, Lloyd B. Jeffs, Lorne R. Palmer
Abstract: This invention is in the field of molecular biology, gene expression, functional genomics, and bioinformatics and relates to novel RNA and related structures and methods of use thereof that enables modulation of gene expression and preservation of particular transcriptome targets. The invention contemplates various applications of RNA sequences derived from the genomic RNA of flaviviruses (FVs) and the application of such features in combination with heterologous sequences.
Type:
Grant
Filed:
February 11, 2021
Date of Patent:
August 1, 2023
Assignee:
The Regents of the University of Colorado
Inventors:
Jeffrey S. Kieft, Erich G. Chapman, David A. Costantino, Jay R. Hesselberth, Andrea MacFadden, Benjamin Akiyama
Abstract: Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.
Type:
Grant
Filed:
October 12, 2021
Date of Patent:
August 1, 2023
Assignee:
AVIDITY BIOSCIENCES, INC.
Inventors:
Andrew John Geall, Venkata Ramana Doppalapudi, David Sai-Ho Chu, Michael Caramian Cochran, Michael Hood, Beatrice Diana Darimont, Rob Burke, Yunyu Shi, Gulin Erdogan Marelius, Barbora Malecova
Abstract: In one aspect, described herein is an intronic recognition element for splicing modifier (iREMS) that can be recognized by a compound provided herein. In another aspect, described herein are methods for modulating the amount of a product of a gene, wherein a precursor RNA transcript transcribed from the gene contains an intronic REMS, and the methods utilizing a compound described herein. More particularly, described herein are methods for modulating the amount of an RNA transcript or protein product encoded by a gene, wherein a precursor RNA transcript transcribed from the gene comprises an intronic REMS, and the methods utilizing a compound described herein. In another aspect, provided herein are artificial gene constructs comprising an intronic REMS, and uses of those artificial gene constructs to modulate protein production.
Type:
Grant
Filed:
November 27, 2017
Date of Patent:
July 18, 2023
Assignee:
PTC THERAPEUTICS, INC.
Inventors:
Anuradha Bhattacharyya, Amal Dakka, Kerstin Effenberger, Vijayalakshmi Gabbeta, Wencheng Li, Nikolai Naryshkin, Christopher Trotta, Kari Wiedinger
Abstract: This disclosure relates to novel targets for angiogenic disorders. Novel oligonucleotides are also provided. Methods of using the novel oligonucleotides for the treatment of angiogenic disorders (e.g., preeclampsia) are also provided.
Type:
Grant
Filed:
June 22, 2022
Date of Patent:
July 18, 2023
Assignees:
UNIVERSITY OF MASSACHUSETTS, BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
Abstract: Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality.
Type:
Grant
Filed:
January 7, 2021
Date of Patent:
July 11, 2023
Assignee:
Royal Holloway, University of London
Inventors:
Linda Popplewell, Ian Graham, John George Dickson
Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the programmed cell death 1 ligand 1 (PD-L1) gene, and methods of using such RNAi agents to inhibit expression of a PD-L1 gene and methods of treating subjects having a PD-L1-associated disorder.
Abstract: Disclosed are morpholino oligonucleotides that can be used to silence expression of MGMT, pharmaceutical compositions that include said morpholino oligonucleotides, and methods of using said morpholino oligonucleotides in the treatment of cancer, particularly methods that involve the use of radiation to deliver said morpholino oligonucleotides.
Type:
Grant
Filed:
December 7, 2020
Date of Patent:
June 20, 2023
Assignees:
United States Government As Represented By The Department of Veterans Affairs, Oregon Health & Science University
Inventors:
Prakash Ambady, Jeffrey Wu, Edward Neuwelt
Abstract: Disclosed herein are novel compounds comprising antisense oligonucleotides that regulate the splicing of NUMB. In particular, an antisense oligonucleotide for reducing inclusion of NUMB exon 9 in a population of mature NUMB transcripts is provided. The antisense oligonucleotide comprises a sequence of at least 7 nucleotides that is complementary to a target region within exon 9 of a NUMB transcript. Pharmaceutical compositions comprising the antisense oligonucleotide and methods of treating a proliferative disease using the compounds or compositions of the invention are also described.
Type:
Grant
Filed:
March 19, 2019
Date of Patent:
June 13, 2023
Assignees:
INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS, FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA, FUNDACIÓN DEL SECTOR PÚBLICO ESTATAL CENTRO NACION
Inventors:
Jordi Hernández Ribera, Juan Alberto Valcárcel Juárez, Elias Bechara, Manuel Serrano Marugán, Miguel Rovira Del Olmo, Pablo José Fernández Marcos